PARIS--(BUSINESS WIRE)--Regulatory News:Cellectis (Paris:ALCLS) announces the issuance by the USPTO of US patent 8,921,332 covering chimeric endonucleases for chromosomal gene editing by homologous recombination in cells.
On December the 30th, 2014, the USPTO issued a patent to Institut Pasteur and the Boston Children’s Hospital for a method of nuclease-based chromosomal gene editing in cells in vitro.
This issued patent, filed on February 2000, is part of a patent portfolio owned by Boston Children’s Hospital and Institut Pasteur and licensed exclusively to Cellectis pursuant to a license agreement dated June 2000.
Help employers find you! Check out all the jobs and post your resume.
On December the 30th, 2014, the USPTO issued a patent to Institut Pasteur and the Boston Children’s Hospital for a method of nuclease-based chromosomal gene editing in cells in vitro.
This issued patent, filed on February 2000, is part of a patent portfolio owned by Boston Children’s Hospital and Institut Pasteur and licensed exclusively to Cellectis pursuant to a license agreement dated June 2000.
Help employers find you! Check out all the jobs and post your resume.
